Neurodegenerative diseases
This page brings together the European Medicines Agency's (EMA) latest information on diseases causing problems with the brain and nervous system, including Alzheimer's disease, Parkinson's disease and multiple sclerosis.
It lists the following:
EMA’s human medicines committee (CHMP) recommended 12 medicines for approval at its March 2024 meeting.
EMA has recommended granting a marketing authorisation in the European Union for a new therapy for the treatment of adult patients with amyotrophic lateral sclerosis (ALS), a rare and often fatal disease that causes muscles to become weak and leads to paralysis. Qalsody (tofersen) is indicated for the treatment of adults with ALS, who have a...
EMA’s human medicines committee (CHMP) recommended 10 medicines for approval at its February 2024 meeting.
EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its December 2023 meeting.
Currently, we have no events for this therapeutic area.